copanlisib

Ligand id: 7875

Name: copanlisib

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 10
Hydrogen bond donors 2
Rotatable bonds 9
Topological polar surface area 127.43
Molecular weight 480.22
XLogP 0.22
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Copanlisib demonstrated a broad anti-tumor spectrum in preclinical tumor models and promising early clinical signals in a Phase I study in patients with follicular lymphoma. Phase II clinical trial NCT01660451 for relapsed, indolent or aggressive Non-Hodgkin's lymphomas is underway. In September 2017, copanlisib received FDA approval for the treatment of adults with relapsed follicular lymphoma who have received at least two prior systemic treatments.
Mechanism Of Action and Pharmacodynamic Effects
Activation of the PI3K signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible cell populations.